ABM1310X1101 A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients with Advanced Solid Tumors Harboring BRAF Mutations

Principal Investigator

Macarena De La Fuente

Enrollment Status

Closed

Clinical Trial ID

Institutional Protocol # 20230164

Clinical Trial Summary

A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients with Advanced Solid Tumors Harboring BRAF Mutations

Phase

Phase I

Funding Agency/Sponsor

Industrial

Disease

Neurological Cancer

Contact Information

Phone Number +1 (407) 7659589